On January 2,2023,Cancer Pathogenesis and Therapy(CPT)published an online article entitled“Carrimycin as an anticancer candidate inhibits tumors by targeting selenoprotein H in the nucleus of tumor cells to induce nu...On January 2,2023,Cancer Pathogenesis and Therapy(CPT)published an online article entitled“Carrimycin as an anticancer candidate inhibits tumors by targeting selenoprotein H in the nucleus of tumor cells to induce nuclear oxidative stress and inhibit ribosome biosynthesis,”authored by Yu LC et al.1 from the National Cancer Institute of the National Institutes of Health.Yu LC et al.1 discovered that isovalerylspiramycin I(ISP I)—the key active ingredient of carrimycin2—directly inhibits selenoprotein H(SELH)expression.As the sole antioxidant enzyme in the nucleolus,SELH serves key regulatory roles in relation to numerous oxidants produced during rapid rRNA synthesis.展开更多
文摘On January 2,2023,Cancer Pathogenesis and Therapy(CPT)published an online article entitled“Carrimycin as an anticancer candidate inhibits tumors by targeting selenoprotein H in the nucleus of tumor cells to induce nuclear oxidative stress and inhibit ribosome biosynthesis,”authored by Yu LC et al.1 from the National Cancer Institute of the National Institutes of Health.Yu LC et al.1 discovered that isovalerylspiramycin I(ISP I)—the key active ingredient of carrimycin2—directly inhibits selenoprotein H(SELH)expression.As the sole antioxidant enzyme in the nucleolus,SELH serves key regulatory roles in relation to numerous oxidants produced during rapid rRNA synthesis.
